Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology
10 affiliations
- 1Division of Pathology and Somatic Molecular Diagnostics, European Institute of Oncology IRCCS, Milan, Italy
- 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- 3European Society of Pathology, Brussels, Belgium
- 4Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, Irblleida, Ciberonc, Spain
- 5Institute of Pathology, Heinrich-Heine University and University Hospital of Dusseldorf, Dusseldorf, Germany
- 6The Fingerland Department of Pathology, Charles University Medical Faculty, Hradec Králové, CZ-500 05 Czech Republic
- 7University Hospital, Hradec Králové, Czech Republic
- 8IHU RespirERA, Côte d’Azur University, 30 Avenue de la Voie Romaine, Nice Cedex 01, 06002 France
- 9Hospital-Related Biobank, Côte d’Azur University, 30 Avenue de la Voie Romaine, Nice Cedex 01, BB-0033-00025, 06002 France
- 10FHU OncoAge, Pasteur Hospital, Côte d’Azur University, 30 Avenue de la Voie Romaine, Nice Cedex 01, 06002 France
Abstract
Liquid biopsy (LBx), particularly plasma circulating tumour DNA (ctDNA) analysis, has become an important use case of molecular pathology in solid tumours. While tissue remains the cornerstone of diagnosis, ctDNA testing provides a minimally invasive alternative using repeatable source of tumour-derived genomic information that complements tissue analysis when samples are unavailable, insufficient, outdated, or unlikely to capture tumour heterogeneity and evolution. In this expert opinion paper, the European Society of Pathology (ESP) defines its vision for LBx implementation across Europe and reaffirms the central role of pathology in blood-based detection of genomic alterations in solid tumours. Two clinical models highlight current implementation of LBx into standard diagnostic work-up. In advanced non-small cell lung cancer (NSCLC), LBx enables rapid detection of actionable somatic genomic alterations, supports treatment decisions when tissue biopsy is not available/sufficient for molecular analysis, and identifies acquired resistance genomic alterations at progression. However, tissue remains essential for histological classification, PD-L1 assessment, recognition of histologic transformation, evaluation of tumour microenvironment, and molecular testing when comprehensive genomic profiling or confirmation of liquid biopsy findings is required. In metastatic breast cancer, LBx has become central to dynamic molecular management of patients with originally hormonally dependent disease. This paper also addresses key technical and interpretative challenges, including assay selection, next-generation sequencing, clonal haematopoiesis, tumour fraction, variant allele fraction, co-mutations, testing logistics, and quality assurance. Given heterogeneity in access to LBx testing across Europe, harmonized standards for validation, reporting, training, and equitable availability are urgently needed. Pathology laboratories have a central role in identifying somatic alterations in cancer tissue, and LBx is an obvious extension of this important task. An integrated morphological-molecular pathology assessment is needed to implement appropriate precision oncology strategies. Incorporation of specific professional personal profiles (molecular biologists, bioinformaticians) to pathology laboratories is therefore essential for such optimal approach.
Related
- European training requirements for gynecological oncology: the European Society of Gynaecological Oncology Curriculum
- Comparison of Risk Assessment Strategies Recommended by the 2019 and 2024 European Society of Cardiology Guidelines in Patients With Stable Chest Pain: A Coronary Computed Tomography Angiography Study
- Andes hantavirus outbreak on a cruise ship—an European Society of Clinical Microbiology and Infectious Disease Emerging Infections Subcommittee rapid assessment
- Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti‐Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists
- Radiologically similar bilateral multifocal renal tumours with discordant pathology: a case report of fat-poor angiomyolipoma and contralateral chromophobe renal cell carcinoma.
BibTeX
@article{fusco2026liquid,
title = {{Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology}},
author = {Nicola Fusco and Xavier Matias-Guiu and Irene Esposito and Raed Al Dieri and Aleš Ryška and Paul Hofman},
journal = {Virchows Archiv},
year = {2026},
month = aug,
doi = {10.1007/s00428-026-04690-0},
url = {https://doi.org/10.1007/s00428-026-04690-0},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology
AU - Nicola Fusco
AU - Xavier Matias-Guiu
AU - Irene Esposito
AU - Raed Al Dieri
AU - Aleš Ryška
AU - Paul Hofman
PY - 2026
DA - 2026/08/27
JO - Virchows Archiv
DO - 10.1007/s00428-026-04690-0
UR - https://doi.org/10.1007/s00428-026-04690-0
AB - Liquid biopsy (LBx), particularly plasma circulating tumour DNA (ctDNA) analysis, has become an important use case of molecular pathology in solid tumours. While tissue remains the cornerstone of diagnosis, ctDNA testing provides a minimally invasive alternative using repeatable source of tumour-derived genomic information that complements tissue analysis when samples are unavailable, insufficient, outdated, or unlikely to capture tumour heterogeneity and evolution. In this expert opinion paper, the European Society of Pathology (ESP) defines its vision for LBx implementation across Europe and reaffirms the central role of pathology in blood-based detection of genomic alterations in solid tumours. Two clinical models highlight current implementation of LBx into standard diagnostic work-up. In advanced non-small cell lung cancer (NSCLC), LBx enables rapid detection of actionable somatic genomic alterations, supports treatment decisions when tissue biopsy is not available/sufficient for molecular analysis, and identifies acquired resistance genomic alterations at progression. However, tissue remains essential for histological classification, PD-L1 assessment, recognition of histologic transformation, evaluation of tumour microenvironment, and molecular testing when comprehensive genomic profiling or confirmation of liquid biopsy findings is required. In metastatic breast cancer, LBx has become central to dynamic molecular management of patients with originally hormonally dependent disease. This paper also addresses key technical and interpretative challenges, including assay selection, next-generation sequencing, clonal haematopoiesis, tumour fraction, variant allele fraction, co-mutations, testing logistics, and quality assurance. Given heterogeneity in access to LBx testing across Europe, harmonized standards for validation, reporting, training, and equitable availability are urgently needed. Pathology laboratories have a central role in identifying somatic alterations in cancer tissue, and LBx is an obvious extension of this important task. An integrated morphological-molecular pathology assessment is needed to implement appropriate precision oncology strategies. Incorporation of specific professional personal profiles (molecular biologists, bioinformaticians) to pathology laboratories is therefore essential for such optimal approach.
SN - 0945-6317
SN - 1432-2307
ER -